

Nihar Kinarivala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2548104/publications.pdf>

Version: 2024-02-01

16
papers

353
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

606
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3477-3510.	3.0	83
2	Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5. <i>ChemMedChem</i> , 2017, 12, 1033-1044.	3.2	41
3	Engineering CAR-T cells to activate small-molecule drugs in situ. <i>Nature Chemical Biology</i> , 2022, 18, 216-225.	8.0	39
4	Passage Variation of PC12 Cells Results in Inconsistent Susceptibility to Externally Induced Apoptosis. <i>ACS Chemical Neuroscience</i> , 2017, 8, 82-88.	3.5	36
5	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9739-9756.	6.4	32
6	Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 842-874.	1.7	19
7	Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1089-1103.	3.7	17
8	Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4415-4427.	6.4	16
9	An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 931-947.	4.9	14
10	Pharmacophore elucidation of phosphodiacyl A " Potent and selective peroxisome proliferator-activated receptor α agonists with neuroprotective activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1889-1893.	2.2	13
11	Exploration of relative chemoselectivity in the hydrodechlorination of 2-chloropyridines. <i>Tetrahedron Letters</i> , 2014, 55, 5386-5389.	1.4	11
12	Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12705-12722.	6.4	10
13	Rational approaches for the design of various GABA modulators and their clinical progression. <i>Molecular Diversity</i> , 2021, 25, 551-601.	3.9	9
14	Exogenous Flupirtine as Potential Treatment for CLN3 Disease. <i>Cells</i> , 2020, 9, 1872.	4.1	6
15	Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 288-315.	1.7	5
16	Gram-scale preparation of the antibiotic lead compound salicyl-AMS, a potent inhibitor of bacterial salicylate adenylation enzymes. <i>Methods in Enzymology</i> , 2020, 638, 69-87.	1.0	2